Potent gastric acid inhibition in Helicobacter pylori eradication
- PMID: 16335862
- DOI: 10.2165/00003495-200565001-00012
Potent gastric acid inhibition in Helicobacter pylori eradication
Abstract
At present, antisecretory drugs--foremost among them the proton pump inhibitors (PPIs)--represent a keystone in Helicobacter pylori eradication therapy. The present article shall first compare the role of PPIs as compared with histamine H2 receptor antagonists, both of them in the role of antibiotic-associated antisecretory therapy, and shall then address the contribution of each of the various PPIs that have been developed until the present time to the H. pylori eradication therapies. In summary, it may be concluded that PPIs are more effective overall than H2 receptor antagonists when the two groups of antisecretory drugs are given at the usual standard doses together with antibiotics with the intention of eradicating H. pylori infection. However, all PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole) are equivalent when given together with two antibiotics to cure the infection.
Similar articles
-
[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].Nihon Rinsho. 1999 Jan;57(1):153-6. Nihon Rinsho. 1999. PMID: 10036954 Review. Japanese.
-
Formulary management of proton pump inhibitors.Pharmacoeconomics. 1999 Sep;16(3):225-46. doi: 10.2165/00019053-199916030-00002. Pharmacoeconomics. 1999. PMID: 10558037 Review.
-
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.Aliment Pharmacol Ther. 1997 Apr;11 Suppl 1:21-5. doi: 10.1046/j.1365-2036.11.s1.4.x. Aliment Pharmacol Ther. 1997. PMID: 9146787 Review.
-
[Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].Z Gastroenterol. 1996 May;34(5):267-72. Z Gastroenterol. 1996. PMID: 8686357 German.
-
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.Helicobacter. 2007 Dec;12(6):638-42. doi: 10.1111/j.1523-5378.2007.00556.x. Helicobacter. 2007. PMID: 18001407 Clinical Trial.
Cited by
-
Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.Clin Exp Med. 2018 Nov;18(4):569-576. doi: 10.1007/s10238-018-0510-9. Epub 2018 Jun 6. Clin Exp Med. 2018. PMID: 29876770 Clinical Trial.
-
Protective effects of a triple-fermented barley extract (FBe) against HCl/EtOH-induced gastric mucosa damage in mice.Food Sci Nutr. 2018 Oct 1;6(8):2036-2046. doi: 10.1002/fsn3.745. eCollection 2018 Nov. Food Sci Nutr. 2018. PMID: 30510705 Free PMC article.
-
Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori.Biomed Res Int. 2021 Apr 10;2021:6150628. doi: 10.1155/2021/6150628. eCollection 2021. Biomed Res Int. 2021. PMID: 33937401 Free PMC article. Clinical Trial.
-
Optimum duration of regimens for Helicobacter pylori eradication.Cochrane Database Syst Rev. 2013 Dec 11;2013(12):CD008337. doi: 10.1002/14651858.CD008337.pub2. Cochrane Database Syst Rev. 2013. PMID: 24338763 Free PMC article.
-
Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.Drugs. 2009 Jul 9;69(10):1373-401. doi: 10.2165/00003495-200969100-00007. Drugs. 2009. PMID: 19583455 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical